PRAXIS PRECISION MEDICINES, INC. Net Income
PRAXIS PRECISION MEDICINES, INC. (PRAX) reported Net Income of -$83.72 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:NetIncomeLoss · last filed 2026-08-06
- PRAXIS PRECISION MEDICINES, INC. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$83.72M.
- PRAXIS PRECISION MEDICINES, INC. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$92.56M.
- PRAXIS PRECISION MEDICINES, INC. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$88.64M.
- PRAXIS PRECISION MEDICINES, INC. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$73.93M.
- PRAXIS PRECISION MEDICINES, INC. net income (loss) attributable to parent for fiscal 2020 was -$61.82M.
- PRAXIS PRECISION MEDICINES, INC. net income (loss) attributable to parent for fiscal 2019 was -$35.51M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$83.72M 10-Q · filed 2026-08-06 | -$176.28M 10-Q · filed 2026-08-06 | -$264.92M derived: sum of 3 quarters · filed 2026-08-06 | -$338.86M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | -$92.56M 10-Q · filed 2026-08-06 | -$181.20M derived: sum of 2 quarters · filed 2026-08-06 | -$255.14M derived: sum of 3 quarters · filed 2026-08-06 | -$326.26M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | -$88.64M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-30 | -$162.58M derived: sum of 2 quarters · filed 2026-04-30 | -$233.70M derived: sum of 3 quarters · filed 2026-08-06 | -$303.00M DEF 14A · filed 2026-04-30 | -$303.27M 10-K · filed 2026-02-19 |
| 2025-09-30 | -$73.93M 10-Q · filed 2025-11-05 | -$145.06M derived: sum of 2 quarters · filed 2026-08-06 | -$214.36M 10-Q · filed 2025-11-05 | -$273.04M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | -$71.13M 10-Q · filed 2026-08-06 | -$140.42M 10-Q · filed 2026-08-06 | -$199.10M derived: sum of 3 quarters · filed 2026-08-06 | -$251.01M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | -$69.30M 10-Q · filed 2026-08-06 | -$127.97M derived: sum of 2 quarters · filed 2026-08-06 | -$179.88M derived: sum of 3 quarters · filed 2026-08-06 | -$212.56M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2024-12-31 | -$58.68M 10-K · filed 2025-02-28 | -$110.59M derived: sum of 2 quarters · filed 2025-11-05 | -$143.27M derived: sum of 3 quarters · filed 2025-11-05 | -$183.00M DEF 14A · filed 2026-04-30 | -$182.82M 10-K · filed 2025-02-28 |
| 2024-09-30 | -$51.91M 10-Q · filed 2025-11-05 | -$84.59M derived: sum of 2 quarters · filed 2025-11-05 | -$124.14M 10-Q · filed 2025-11-05 | -$151.02M derived: sum of 4 quarters · filed 2025-11-05 | |
| 2024-06-30 | -$32.68M 10-Q · filed 2025-11-05 | -$72.23M 10-Q · filed 2025-08-04 | -$99.11M derived: sum of 3 quarters · filed 2025-11-05 | -$123.74M derived: sum of 4 quarters · filed 2025-11-05 | |
| 2024-03-31 | -$39.55M 10-Q · filed 2025-11-05 | -$66.43M derived: sum of 2 quarters · filed 2025-11-05 | -$91.06M derived: sum of 3 quarters · filed 2025-11-05 | -$125.38M derived: sum of 4 quarters · filed 2025-11-05 | |
| 2023-12-31 | -$26.88M 10-K · filed 2025-02-28 | -$51.51M derived: sum of 2 quarters · filed 2025-02-28 | -$85.82M derived: sum of 3 quarters · filed 2025-02-28 | -$123.00M DEF 14A · filed 2026-04-30 | -$123.28M 10-K · filed 2024-03-05 |
| 2023-09-30 | -$24.63M 10-K · filed 2025-02-28 | -$58.94M derived: sum of 2 quarters · filed 2025-02-28 | -$96.40M 10-Q · filed 2024-11-06 | -$137.57M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2023-06-30 | -$34.31M 10-K · filed 2025-02-28 | -$71.77M 10-Q · filed 2024-08-13 | -$112.94M derived: sum of 3 quarters · filed 2025-02-28 | -$156.88M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2023-03-31 | -$37.45M 10-K · filed 2025-02-28 | -$78.63M derived: sum of 2 quarters · filed 2025-02-28 | -$122.57M derived: sum of 3 quarters · filed 2025-02-28 | -$182.77M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2022-12-31 | -$41.17M 10-K · filed 2024-03-05 | -$85.12M derived: sum of 2 quarters · filed 2024-03-05 | -$145.31M derived: sum of 3 quarters · filed 2024-03-05 | -$214.00M DEF 14A · filed 2026-04-30 | -$214.03M 10-K · filed 2023-02-07 |
| 2022-09-30 | -$43.95M 10-K · filed 2024-03-05 | -$104.14M derived: sum of 2 quarters · filed 2024-03-05 | -$172.86M 10-Q · filed 2023-11-07 | -$231.44M derived: sum of 4 quarters · filed 2024-03-05 | |
| 2022-06-30 | -$60.19M 10-K · filed 2024-03-05 | -$128.91M 10-Q · filed 2023-08-09 | -$187.49M derived: sum of 3 quarters · filed 2024-03-05 | -$232.20M derived: sum of 4 quarters · filed 2024-03-05 | |
| 2022-03-31 | -$68.72M 10-K · filed 2024-03-05 | -$127.30M derived: sum of 2 quarters · filed 2024-03-05 | -$172.00M derived: sum of 3 quarters · filed 2024-03-05 | -$208.41M derived: sum of 4 quarters · filed 2024-03-05 | |
| 2021-12-31 | -$58.58M 10-K · filed 2023-02-07 | -$103.29M derived: sum of 2 quarters · filed 2023-02-07 | -$139.69M derived: sum of 3 quarters · filed 2023-02-07 | -$167.00M DEF 14A · filed 2026-04-30 | -$167.06M 10-K · filed 2022-02-28 |
| 2021-09-30 | -$44.70M 10-K · filed 2023-02-07 | -$81.11M derived: sum of 2 quarters · filed 2023-02-07 | -$108.48M 10-Q · filed 2022-11-09 | -$134.19M derived: sum of 4 quarters · filed 2023-02-07 | |
| 2021-06-30 | -$36.40M 10-K · filed 2023-02-07 | -$63.77M 10-Q · filed 2022-08-08 | -$89.48M derived: sum of 3 quarters · filed 2023-02-07 | -$105.70M derived: sum of 4 quarters · filed 2023-02-07 | |
| 2021-03-31 | -$27.37M 10-K · filed 2023-02-07 | -$53.08M derived: sum of 2 quarters · filed 2023-02-07 | -$69.30M derived: sum of 3 quarters · filed 2023-02-07 | -$80.86M derived: sum of 4 quarters · filed 2023-02-07 | |
| 2020-12-31 | -$25.71M 10-K · filed 2022-02-28 | -$41.92M derived: sum of 2 quarters · filed 2022-02-28 | -$53.49M derived: sum of 3 quarters · filed 2022-02-28 | -$61.82M 10-K · filed 2022-02-28 | |
| 2020-09-30 | -$16.22M 10-K · filed 2022-02-28 | -$27.78M derived: sum of 2 quarters · filed 2022-02-28 | -$36.11M 10-Q · filed 2021-11-03 | -$43.50M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-06-30 | -$11.57M 10-K · filed 2022-02-28 | -$19.90M 10-Q · filed 2021-08-16 | -$27.29M derived: sum of 3 quarters · filed 2022-02-28 | -$37.89M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-03-31 | -$8.33M 10-K · filed 2022-02-28 | -$15.72M derived: sum of 2 quarters · filed 2022-02-28 | -$26.32M derived: sum of 3 quarters · filed 2022-02-28 | ||
| 2019-12-31 | -$7.39M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-17 | -$17.99M derived: sum of 2 quarters · filed 2021-03-17 | -$35.51M 10-K · filed 2021-03-17 | ||
| 2019-09-30 | -$10.61M 10-Q · filed 2020-11-23 | -$28.12M 10-Q · filed 2020-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |